In this prospective study, we investigated the efficacy and safety of pembrolizumab monotherapy as a first-line treatment in patients with advanced NSCLC with PD-L1 TPS positivity who either had PS 2 or were elderly patients aged ≥ 75 years. The gene discussed is CD274; the disease is non-small cell lung carcinoma.